Memorial Sloan Kettering Cancer Center
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT02833233
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Using a Patient-Centered mHealth Intervention to Improve Adherence to Oral Anticancer Medications
- Conditions
- SarcomaSolid Tumor GastrointestinalLung
- Interventions
- Other: SMS/MMS text messagingOther: usual care
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT02833246
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer
- Conditions
- Castration Resistant Prostate CancerProstate Cancer
- Interventions
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT02833883
- Locations
- πΊπΈ
University of California San Francisco, San Francisco, California, United States
πΊπΈJohn Hopkins Medical Center, Baltimore, Maryland, United States
πΊπΈDuke University Medical Center, Durham, North Carolina, United States
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
- Conditions
- Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT02831686
- Locations
- πΊπΈ
Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
πΊπΈMemorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
πΊπΈMemorial Sloan Kettering Nassau, Uniondale, New York, United States
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
- Conditions
- Merkel Cell CarcinomaMelanomaOther Solid Tumors
- Interventions
- Drug: TALIMOGENE LAHERPAREPVEC (TVEC)Radiation: Hypofractionated Radiotherapy
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT02819843
- Locations
- πΊπΈ
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
πΊπΈMemorial Sloan Kettering Westchester, Harrison, New York, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
Web-based Patient Education Program to Manage Side Effects of Allogeneic Stem Cell Transplant
- Conditions
- Allo-SCT PatientsAdult Allo-SCT Survivor
- Interventions
- Other: web-based patient educationBehavioral: questionnaire
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT02812082
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Utility of Intra-operative Image Guidance System for Missing Metastases
- Conditions
- Colorectal CancerMetastatic to the Liver
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT02806037
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
- Conditions
- EGFR-mutant Lung CancersNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT02803203
- Locations
- πΊπΈ
Memorial Sloan Kettering commack, Commack, New York, United States
πΊπΈMemorial Sloan Kettering Westchester, Harrison, New York, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
T-Cell Therapy for Advanced Breast Cancer
- Conditions
- Breast CancerMetastatic HER2-negative Breast
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 186
- Registration Number
- NCT02792114
- Locations
- πΊπΈ
Memorial Sloan Kettering Westchester (Consent and follow-up only), Harrison, New York, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈMemorial Sloan Kettering Cancer Center (Consent and follow-up only), Basking Ridge, New Jersey, United States
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
- Conditions
- LymphomaRelapsed/Refractory T-cell Lymphomas
- Interventions
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 114
- Registration Number
- NCT02783625
- Locations
- πΊπΈ
Stanford University Medical Center, Stanford, California, United States
πΊπΈUniversity of Washington School of Medicine in St. Louis, Saint Louis, Missouri, United States
πΊπΈWashington University School of Medicine, Saint Louis, Missouri, United States